Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab + DCF in advanced gastric cancer
NCT01716546Phase 2Terminated
- Sponsor
- Hellenic Oncology Research Group
- Start
- Jul 2011
- Primary completion
- Jan 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Hellenic Oncology Research Group. Started Jul 2011; status: terminated.
02
Drugs
panitumumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01716546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01716546.